These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 20417241)

  • 1. NAP (davunetide) enhances cognitive behavior in the STOP heterozygous mouse--a microtubule-deficient model of schizophrenia.
    Merenlender-Wagner A; Pikman R; Giladi E; Andrieux A; Gozes I
    Peptides; 2010 Jul; 31(7):1368-73. PubMed ID: 20417241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microtubules, schizophrenia and cognitive behavior: preclinical development of davunetide (NAP) as a peptide-drug candidate.
    Gozes I
    Peptides; 2011 Feb; 32(2):428-31. PubMed ID: 21050875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New horizons in schizophrenia treatment: autophagy protection is coupled with behavioral improvements in a mouse model of schizophrenia.
    Merenlender-Wagner A; Shemer Z; Touloumi O; Lagoudaki R; Giladi E; Andrieux A; Grigoriadis NC; Gozes I
    Autophagy; 2014; 10(12):2324-32. PubMed ID: 25484074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model.
    Vulih-Shultzman I; Pinhasov A; Mandel S; Grigoriadis N; Touloumi O; Pittel Z; Gozes I
    J Pharmacol Exp Ther; 2007 Nov; 323(2):438-49. PubMed ID: 17720885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Altered expression of synaptic protein mRNAs in STOP (MAP6) mutant mice.
    Eastwood SL; Lyon L; George L; Andrieux A; Job D; Harrison PJ
    J Psychopharmacol; 2007 Aug; 21(6):635-44. PubMed ID: 17050659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cognitive impairments in the STOP null mouse model of schizophrenia.
    Powell KJ; Hori SE; Leslie R; Andrieux A; Schellinck H; Thorne M; Robertson GS
    Behav Neurosci; 2007 Oct; 121(5):826-35. PubMed ID: 17907815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microtubules (tau) as an emerging therapeutic target: NAP (davunetide).
    Gozes I
    Curr Pharm Des; 2011; 17(31):3413-7. PubMed ID: 21902667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The influence of the peptide NAP on Mac-1-deficient mice following closed head injury.
    Zaltzman R; Alexandrovich A; Trembovler V; Shohami E; Gozes I
    Peptides; 2005 Aug; 26(8):1520-7. PubMed ID: 16042992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The deletion of STOP/MAP6 protein in mice triggers highly altered mood and impaired cognitive performances.
    Fournet V; Schweitzer A; Chevarin C; Deloulme JC; Hamon M; Giros B; Andrieux A; Martres MP
    J Neurochem; 2012 Apr; 121(1):99-114. PubMed ID: 22146001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microtubule stabilizer ameliorates synaptic function and behavior in a mouse model for schizophrenia.
    Andrieux A; Salin P; Schweitzer A; Bégou M; Pachoud B; Brun P; Gory-Fauré S; Kujala P; Suaud-Chagny MF; Höfle G; Job D
    Biol Psychiatry; 2006 Dec; 60(11):1224-30. PubMed ID: 16806091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression pattern of STOP lacZ reporter gene in adult and developing mouse brain.
    Couégnas A; Schweitzer A; Andrieux A; Ghandour MS; Boehm N
    J Neurosci Res; 2007 May; 85(7):1515-27. PubMed ID: 17394261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cytoskeleton as a drug target for neuroprotection: the case of the autism- mutated ADNP.
    Gozes I
    Biol Chem; 2016 Mar; 397(3):177-84. PubMed ID: 25955282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel davunetide (NAPVSIPQQ to NAPVSIPQE) point mutation in activity-dependent neuroprotective protein (ADNP) causes a mild developmental syndrome.
    Gozes I; Shazman S
    Eur J Neurosci; 2023 Jul; 58(2):2641-2652. PubMed ID: 36669790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The stop null mice model for schizophrenia displays [corrected] cognitive and social deficits partly alleviated by neuroleptics.
    Bégou M; Volle J; Bertrand JB; Brun P; Job D; Schweitzer A; Saoud M; D'Amato T; Andrieux A; Suaud-Chagny MF
    Neuroscience; 2008 Nov; 157(1):29-39. PubMed ID: 18804150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microtubule-stabilizing peptides and small molecules protecting axonal transport and brain function: focus on davunetide (NAP).
    Magen I; Gozes I
    Neuropeptides; 2013 Dec; 47(6):489-95. PubMed ID: 24210139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risperidone and NAP protect cognition and normalize gene expression in a schizophrenia mouse model.
    Vaisburd S; Shemer Z; Yeheskel A; Giladi E; Gozes I
    Sci Rep; 2015 Nov; 5():16300. PubMed ID: 26553741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypoglutamatergic activity in the STOP knockout mouse: a potential model for chronic untreated schizophrenia.
    Brenner E; Sonnewald U; Schweitzer A; Andrieux A; Nehlig A
    J Neurosci Res; 2007 Nov; 85(15):3487-93. PubMed ID: 17304567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phencyclidine and genetic animal models of schizophrenia developed in relation to the glutamate hypothesis.
    Enomoto T; Noda Y; Nabeshima T
    Methods Find Exp Clin Pharmacol; 2007 May; 29(4):291-301. PubMed ID: 17609743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity-dependent neuroprotective protein: from gene to drug candidate.
    Gozes I
    Pharmacol Ther; 2007 May; 114(2):146-54. PubMed ID: 17363064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity-dependent neuroprotective protein (ADNP)-end-binding protein (EB) interactions regulate microtubule dynamics toward protection against tauopathy.
    Ivashko-Pachima Y; Gozes I
    Prog Mol Biol Transl Sci; 2021; 177():65-90. PubMed ID: 33453943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.